Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.28 USD | +2.70% | -0.90% | +31.87% |
13/05 | Piper Sandler Adjusts Price Target on Myriad Genetics to $28 From $23, Maintains Neutral Rating | MT |
08/05 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.87% | 2.23B | |
-4.57% | 12.33B | |
-4.35% | 8.14B | |
+30.70% | 5.62B | |
-8.09% | 4.24B | |
-54.61% | 3.06B | |
+14.44% | 2.76B | |
-1.18% | 2.41B | |
-4.67% | 1.87B | |
+3.02% | 1.58B |
- Stock Market
- Equities
- MYGN Stock
- News Myriad Genetics, Inc.
- JPMorgan Adjusts Myriad Genetics' Price Target to $17 From $18, Keeps Underweight Rating